Roy Eldor
6PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jul 17, 2025
Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen.Roy Eldor, Noa Avraham, Orit Rosenberg
|Jul 15, 2025
Novel oral agents in anti-obesity pharmacotherapy: A narrative review.Assaf Buch, Roy Eldor, Roy Brown
|Jan 25, 2024
Clinical characteristics and healthcare utilisation associated with undiagnosed cognitive impairment in elderly patients with diabetes in a primary care setting: a population-based cohort study.Eugene Merzon, Miriam Shpigelman, Shlomo Vinker
|Oct 25, 2022
Oral insulin (ORMD-0801) in type 2 diabetes mellitus: A dose-finding 12-week randomized placebo-controlled study.Roy Eldor, Bruce H Francis, Alexander Fleming
|Jul 26, 2021
Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes: A randomized, placebo-controlled trial.Roy Eldor, Joel Neutel, Kenneth Homer
|Dec 21, 2017
Increased lipid availability for three days reduces whole body glucose uptake, impairs muscle mitochondrial function and initiates opposing effects on PGC-1α promoter methylation in healthy subjects.Roy Eldor, Luke Norton, Marcel Fourcaudot
Pageof 1
